← All Sponsors
SPONSOR

Axsome Therapeutics, Inc.

Total Trials
2
Recruiting
2
Phases
Phase 3
Conditions studied: FibromyalgiaExcessive SleepinessShift-work Disorder
NCT07398417 Phase 3
Recruiting

Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design

Fibromyalgia
United States View Trial →
NCT06568367 Phase 3
Recruiting

Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

Excessive Sleepiness
United States, Canada View Trial →